The KBTBD6 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population designed for loss-of-function studies of the KBTBD6 gene in a human lung adenocarcinoma background. This product is generated via CRISPR/Cas9-mediated gene disruption in the A-549 cell line, resulting in a heterogeneous pool of cells with targeted KBTBD6 ablation. As a polyclonal knockout resource, it enables the analysis of bulk population effects while preserving the biological variability inherent in non-clonal gene-edited cultures. The knockout model serves as a starting point for investigating KBTBD6-dependent mechanisms in cancer-relevant contexts without the need for single-cell cloning.
The A-549 host cell line is an established model derived from the lung adenocarcinoma tissue of a 58-year-old Caucasian male. These cells exhibit an epithelial morphology consistent with type II alveolar epithelial origin and carry a well-characterized KRAS G12S oncogenic mutation. They are widely employed in non-small cell lung cancer research for studying tumor biology, drug responses, and signal transduction. The KRAS-mutant background provides a clinically relevant framework for evaluating gene functions that intersect with oncogenic KRAS signaling, enhancing the utility of the KBTBD6 knockout in lung adenocarcinoma studies.
KBTBD6 encodes a substrate recognition adaptor of the Cullin3-RING E3 ubiquitin ligase (CRL3) complex, which comprises CUL3, RBX1, and the ubiquitin-like protein NEDD8. This complex facilitates the polyubiquitination of specific target proteins, marking them for degradation by the 26S proteasome. Through its interaction with CUL3, KBTBD6 recruits substrates to the ligase, thereby controlling their abundance and downstream cellular functions. While the full spectrum of KBTBD6 substrates remains undefined, its role in the ubiquitin-proteasome system positions it as a potential modulator of protein networks involved in cell cycle progression and signaling, possibly including elements of the Wnt pathway.
In the A-549 KRAS-mutant context, disruption of KBTBD6 may alter the degradation dynamics of proteins that regulate proliferation and survival, offering insights into how ubiquitin-dependent proteolysis contributes to lung adenocarcinoma pathogenesis. The polyclonal knockout pool permits the study of population-level phenotypic changes, such as shifts in cell growth rates, viability under stress, or sensitivity to chemotherapeutic agents. Because the model is not clonal, it captures a range of editing outcomes, which can be advantageous for detecting robust biological effects across a heterogeneous cell population and for assessing the general impact of KBTBD6 loss.
Researchers can utilize these KBTBD6 knockout A-549 polyclonal cells in a variety of experimental workflows, including Western blotting and RT-qPCR to validate knockout. Ubiquitination assays with proteasome inhibition can aid in substrate identification, while cell viability and colony formation assays assess tumorigenic potential. Flow cytometry for cell cycle analysis and drug sensitivity testing further link KBTBD6 to KRAS-driven lung cancer phenotypes. This polyclonal knockout model supports detailed exploration of ubiquitin-dependent regulation in cancer. Contact Ascent Research for more information.
